NCT07053436View on ClinicalTrials.gov

Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2035

Study Completion Date

October 12, 2035

Conditions
High Risk Newly Diagnosed Multiple Myeloma
Interventions
DRUG

Bispecific Monoclonal Antibody and Triplet Therapy

Induction, Consolidation, and Maintenance Therapy Combining Linvoseltamab and Triplet Therapy

DRUG

Monoclonal Antibody with Stem Cell Transplant

Isatuximab-KRd with Autologous Stem Cell Transplant

All Listed Sponsors
lead

Multiple Myeloma Research Consortium

NETWORK